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A rare homozygous BCS1Lc.A232G (Ser78Gly, p.S78G) mutation in infants causes GRACILE 
syndrome, which is a severe mitochondrial respiratory chain complex III (CIII) disorder resulting in 
multiple organ dysfunction and early lethality. Pathogenesis mechanisms have been studied using 
our viable Bcs1lp.S78G knock-in mouse model. The mouse model replicates most clinical phenotypes, 
such as growth restriction, hepatopathy, and tubulopathy. Like patients, the survival of homozygous 
mice is reduced (to 35-45 days, P35-P45 in the C57BL/6JBomTac background), mainly because of 
severe hypoglycemia. Aiming to improve the glycemic balance we performed an intervention with a 
high sugar (60% dextrose) diet. This diet did not improve energy metabolism and resulted in 
slightly decreased survival despite apparent normalization of some plasma metabolites.  
For subsequent studies, we bred the Bcs1lc.A232G mutation into a C57BL/6JCrl background, in which 
the survival was five-fold longer (approximately 200 days). Moreover, the extended survival 
brought novel phenotypes, such as encephalopathy and late-onset cardiomyopathy. In this genetic 
background, we investigated the effect of ketogenic diet on disease progression. The ketogenic diet 
had a beneficial impact on liver disease, but it had adverse effects upon long-term feeding, resulting 
in shortened survival. In the third study, we introduced an alternative oxidase (AOX) transgene into 
the Bcs1lp.S78G mice to improve respiratory chain function. The ubiquitous expression of AOX, 
which should bypass electron transfer and relieve CIII blockade, prevented lethal cardiomyopathy 
and renal-tubular atrophy, and delayed focal astrogliosis in the somatosensory cortex of the brain. 
The beneficial effects of AOX extended the median survival of the homozygotes to median P590.  
The main conclusions from these studies are that the Bcs1lp.S78G mice in a C57BL/6JCrl background 
present with both the known early-onset manifestations of GRACILE syndrome and some later-
onset manifestations found in other CIII deficiencies. The dietary interventions had limited benefits, 
probably because of a severe course of the disease. In contrast, bypassing the blocked electron flow 
using AOX had a robust beneficial effect, mainly in tissues or cells with high ATP demand such as 





Mitochondrial disorders are common inborn errors of metabolism and vary widely in their 
presenting age and symptoms. The genetic cause may be an inherited or acquired mutation(s) either 
in the nuclear DNA (nDNA) or mitochondrial DNA (mtDNA). The products of more than  
1000 genes encoded in nDNA and 37 genes in mtDNA play a role in both biogenesis and functions 
of mitochondria, including mitochondrial respiration by the respiratory chain (RC) complexes. 
Furthermore, a specific mutation in either genome can cause mitochondrial dysfunction which 
results in a wide range of diseases and pathological conditions.  
With the current developments in clinical diagnostics, including advanced molecular genetics, it is 
often possible to identify the causative mutation(s) of disease. However, effective treatments are 
currently not available for mitochondrial disorders, despite several promising drugs that affect 
various energy-metabolism pathways in RC deficiency. To develop effective therapeutic strategies, 
detailed knowledge of disease mechanisms is necessary.  
This thesis work is based on the need to understand disease mechanisms in GRACILE syndrome, 
which is by far the most severe RC complex III (CIII) disorder (Fellman et al. 1998). Its cause is a 
homozygous c.A232G mutation in nuclear DNA gene encoding BCS1L, which is an assembly 
factor for CIII. This mutation changes a single amino acid (serine 78 to glycine) in the protein 
(Visapää et al. 2002), which in turn affects CIII assembly. The resulting typical phenotype consists 
of severe fetal Growth Restriction, Aminoaciduria, due to Fanconi type proximal tubulopathy, 
Cholestasis, Iron accumulation, Lactic acidosis, and Early death during infancy, the base for the 
acronym (Fellman et al. 1998, Visapää et al. 2002). The particular genotype-phenotype consistency 
in infants (Fellman et al. 2008) motivated Professor Fellman’s group to generate a mouse model by 
introducing the patient mutation into the mouse genome (Levéen et al. 2011). It resulted in the first 
viable mouse model for CIII deficiency, mimicking the human disease, but with an initial symptom-
free postnatal period. Breeding the mutation into the C57BL/6JCrl background at the University of 
Helsinki resulted in longer survival and additional phenotypes. We used both mouse strains for 





2 Review of the literature  
2.1 The origin and structure of mitochondria 
Mitochondria are double membrane-bound organelles that generate ATP using aerobic respiration 
and also participate in the signaling pathways for cell cycle, differentiation, and death  
(McBride et al. 2006). The current widely-accepted theory about the origin of the mitochondrion is 
the endosymbiont theory. It posits that an archaeon engulfed an alpha-proteobacterium in building a 
symbiotic relationship, resulting in a primitive eukaryotic cell (Martin et al. 2015). Unlike other 
organelles, mitochondria function through proteins encoded both in the nucleus and mitochondrial 
DNA (mtDNA). Mammalian mitochondria have double-stranded circular mtDNA consisting of  
15-17 kbp with a heavy strand (guanine-rich) containing 28 genes and a light strand (cytosine-rich) 
with 9 genes. Of these 37 genes, 22 encode transfer RNA, 2 encode ribosomal RNA, and 13 encode 
polypeptides, which are subunits of mitochondrial respiratory complexes (Taanman 1999).  
The mtDNA is present in the internal space called the matrix that is abundant with enzymes, 
peptides, and proteins, which play a role in the metabolic processes such as pyruvate and fatty acid 
oxidation, and tricarboxylic acid (TCA) cycle. The matrix is enclosed by two phospholipid bilayers. 
They is an inner mitochondrial membrane (IMM) and an outer mitochondrial membrane (OMM), 
separated by an inter-membrane space (IMS). The OMM maintains the integrity of the 
mitochondrion structure and separates inner contents from the cytosol. The OMM contains various 
enzymes involved in metabolic processes (e.g., fatty acid elongation) (Howard 1970) and 
membrane transport. Transportation of large proteins occurs directly by translocase proteins, and 
small molecules such as ions and ATP (<5 kDa) pass through the channels and transporters  
(i.e., porin) (Endo & Kohda 2002). The IMM folding forms the cristae that provide space for the 
IMM-located enzymes and proteins to enhance RC complex activity (Bartolák-Suki et al. 2017). 
2.1.1 Mitochondria in ATP generation 
One of the many important functions of mitochondria is ATP synthesis, mainly by the IMM-located 
ATP synthase (complex V, CV). The CV requires a proton gradient generated by electron transfer 
through RC complexes. The RC complexes are NADH dehydrogenase (complex I, CI), succinate 
dehydrogenase (complex II, CII), cytochrome c reductase (complex III, CIII), and cytochrome c 
oxidase (complex IV, CIV). These RC complexes exist either in free form or are combined to form 
so-called supercomplexes (SC) such as CI/III2/IV, CI/III2, and CIII2/IVn (Schägger 2001). They are 




Figure 1. Schematic structure of the mitochondrion and the respiratory chain complexes in 
the IMM. IMM, inner mitochondrial membrane; IMS, intermembrane space; OMM, outer 
mitochondrial membrane; CI, complex I; CII, Complex II; CIII, Complex III; CIV, Complex IV; 
CV, ATP synthase; UQ, ubiquinol. Red arrows indicate proton translocation, while black arrows 
indicate the direction of electron transfer. Individual RC complex structures in this figure are 
redrawn based on the image provided for the KEGG project by Kanehisa Laboratories. 
 
Complex I oxidizes NADH, which is a product of pyruvate oxidation and TCA cycle. CI releases 
four protons into the IMS and transfers two electrons to reduce ubiquinone (Q), also known as 
coenzyme Q10. CI consists of 45 subunits, among them seven (ND1–ND6 and ND4L) are mtDNA-
encoded proteins forming the major part of the membrane domain (Hirst et al. 2003; Mimaki et al. 
2012), which is involved in proton translocation and ubiquinone binding (Hoogenraad et al. 2002; 
Hirst et al. 2003). The additional 38 subunits are nDNA-encoded proteins, of which seven subunits 
(NDUFV-2, NDUFS1-3, and NDUFS7-8) form the core that oxidizes NADH and initiates electron 
transfer (Vogel et al. 2007; Lazarou et al. 2009). The remaining 31 subunits contribute to the 
structural stability and biogenesis of CI (Friedrich & Böttcher 2004; Mimaki et al. 2012). Complex 
II is not bound to any other complexes and consists of four nDNA-encoded core subunits,  
(SDH-A-D). It dehydrogenates succinate to fumarate, part of the TCA cycle, and transfers electrons 
to Q without proton transfer to the IMS (Cecchini 2003; Ylikallio & Suomalainen 2012).  
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Complex III consists of 10 subunits, of which cytochrome b is mtDNA-encoded, and the rest are 
nDNA-encoded. CIII receives electrons from ubiquinol (QH2) and, transfers them to reduce two 
molecules of cytochrome c, with concomitant translocation of four protons into the IMS 
(Fernandez-Vizarra & Zeviani 2018). Complex IV contains 13 subunits. Three mtDNA-encoded 
proteins are large core subunits (COX1-3) responsible for electron transfer. The other ten nDNA-
encoded subunits stabilize the complex and regulate the biogenesis. CIV re-oxidizes cytochrome c 
and releases two protons into the IMS and converts oxygen molecules into water  
(Fernández-Vizarra et al. 2009).  
In summary, the RC complexes carry out mitochondrial respiration to meet the ATP demand of the 
cell. Impairment of RC complexes disrupts the electron transport chain (ETC) and proton 
translocation, which in turn impairs mitochondrial ATP synthesis (Shi et al. 2008; Xiao et al. 2014). 
Furthermore, ETC disruption can have an indirect impact on metabolic pathways such as glycolysis, 
fatty acid oxidation and the TCA cycle (Zieliński et al. 2016). As the TCA cycle is driven by  
acetyl-CoA from either glycolysis or fatty-acid oxidation to produce NADH and FADH2 for CI and 
CII activity, respectively, impairment of the ETC can inhibit the TCA cycle. 
2.2 CIII assembly and function 
Cryo-EM analysis (Guo et al. 2018) shows CIII in IMM as a tightly packed dimer. Its assembly 
begins with the synthesis of the mtDNA-encoded cytochrome b (CYTB), followed by incorporation 
of nDNA-encoded subunits. The translation factors UQCC1 and UQCC2 bind to CYTB and help to 
stabilize the complex structure during insertion into the IMM. There, bL heme binds to CYTB 
followed by UQCC3, which releases UQCC1 and UQCC2 from their binding. Sequential 
incorporation of bH heme and cytochrome c1 (CYC1) forms the pre-CIII2 dimer into which Rieske 
iron-sulfur protein (RISP) and QCR10 get inserted (Fernandez-Vizarra & Zeviani 2018). The RISP 
precursor is synthesized in the cytosol and translocates through TOM and TIM23 into the 
mitochondrial matrix (Wasilewski et al. 2017). There, a matrix-processing peptidase cleaves part of 
the mitochondrial-transfer sequence (MTS) from the RISP molecule. A LYR-motif-containing 
chaperone (MZM1L/LYRM7) binds to it and recruits the Fe-S transfer complex to form a  
2Fe-2S cluster (Maio et al. 2014; Maio et al. 2017). Thereafter, BCS1L translocates RISP across 
the IMM and incorporates it into the pre-CIII2 (Cruciat et al. 1999; Wagener et al. 2011). 
 TTC19 (Ghezzi et al. 2011) which binds to CIII2 was recently shown to facilitate the removal of 




In the fully assembled CIII2, CYTB, cytochrome c1 (CYC1), and RISP are involved in electron 
transfer by the Q cycle (Figure 2a). CYTB has two Q binding sites (quinone oxidation Qo, and 
quinone reduction Qi sites) and two b-type hemes (bL and bH) (Fernandez-Vizarra & Zeviani 
2018). Electron transfer is initiated from the binding of QH2 and Q at Qo and Qi sites of CYTB, 
respectively. In the Qo site, oxidation of QH2 releases one electron to RISP and subsequently 
another electron to the bL heme of CYTB, accompanied by protonation of His182 of RISP, and 
Glu272 of CYTB (Figure 2b) (Palsdottir et al. 2003). The head domain of RISP releases the proton 
from His182 to IMS and transfers an electron to CYC1. CYC1 transfers the electron further to 
cytochrome c (CYTC), after which CYTC dissociates from CIII2. The proton from Glu272 of 
CYTB is released to IMS through bL heme with the help of a water molecule. Simultaneously, an 
electron from bL heme is transferred via bH heme of CYTB further to Qi site to reduce Q. A single 
electron will partially reduce Q to semiquinone (Figure 2b) (Palsdottir et al. 2003; Crofts et al. 
2017). For complete reduction, the semiquinone acquires another electron which can be generated 
by another cycle of QH2 oxidization at the Qo site. The complete reduction of Q in Qi takes  
2 protons from the matrix. This second cycle of electron transfer reduces the second CYTC and 
releases two more protons into IMS (Crofts et al. 2017).  
 
Figure 2. Crystal structure of yeast cytochrome bc1 complex subunits. a) The tertiary structure 
of CIII subunits (Cytb-cytochrome b, Cyt c1-cytochrome C1, and RISP- Rieske Fe-S protein) and 
their heme clusters. b) Direction of proton and electron transfer in CIII subunits. The structure was 
obtained from the protein data bank (PDB.ID:1KYO). 





2.3 Respiratory chain dysfunction  
Mutations in genes encoding RC subunits lead to RC deficiencies. CI deficiency occurs in patients 
with homozygous or compound heterozygous mutations in genes encoding functional subunits 
(Lazarou et al. 2009), supernumerary subunits, (NDUFS4, S6, NDUFA1-2, and  
NDUFA10-12) (van den Heuvel et al. 1998; Kirby et al. 2004; Fernandez-Moreira et al. 2007; 
Berger et al. 2008; Hoefs et al. 2008; Hoefs et al. 2011), and assembly factors (NDUFAF1-5). 
The clinical manifestations of CI deficiency are diverse, from cardiomyopathy to Leigh syndrome 
(LS), which is a severe neurometabolic disorder with early lethality (Mimaki et al. 2012). Mutations 
in CII subunits (SDHA-D) and assembly factors (SDHAF1-2) cause LS (Hes et al. 2010) and 
paragangliomas (Solis et al. 2009; Hoekstra & Bayley 2013). Mutations affecting CIII are rare and 
mostly in the CYTB gene (Barel et al. 2008) or assembly factors such as TTC19 (Ghezzi et al. 2011; 
Mordaunt et al. 2015) and BCS1L. The number of BCS1L mutations discovered in patients is more 
than 20, and they cause a wide range of clinical phenotypes (Table 1). Mutations in nDNA-encoded 
subunits of CIV, assembly factors (COX10, COX15, and Surf1) (Zhu et al. 1998; Antonicka et al. 
2003a and 2003b), translator activating factor (TACO1) (Weraarpachai et al. 2009), and 
FAST kinase domain-containing protein (FASTKD2) (Ghezzi et al. 2008) can cause a wider 
spectrum of mitochondrial disorders, including LS or Leigh-like diseases, cardiomyopathy, and 
liver failure.  
2.3.1 Reactive oxygen species production in mitochondria 
Reactive oxygen species (ROS) are partially reduced oxygen molecules, such as superoxide, 
hydroxyl radical, and singlet oxygen. In mitochondria, electrons can leak from CI and CIII to 
oxygen, which turns into superoxide (O2-). Superoxide dismutase (SOD) metabolizes superoxides 
further into hydrogen peroxide (H2O2) (Jastroch et al. 2010). Mitochondrial ROS production 
generally depends on the proton motive force, the ratio of NADH/NAD+ and QH2/Q, as well as the 
oxygen concentration (Murphy 2009). Therefore, defective RC function can increase electron leak, 
which results in increased ROS production.  
ROS are involved in the signaling of cell proliferation or apoptosis, depending on their level 
(Schieber & Chandel 2014). A mild increase in ROS regulates cysteine residues and kinases such as 
Akt, ERK1/2, PKA/PKC, JNK, and p38MAPK (Son et al. 2011; Antico Arciuch et al. 2012), which 
can induce the cell anti-apoptotic and proliferation pathways. In contrast, high levels of ROS 
induces cytochrome c release to the cytosol (Ames 1983), which triggers the caspase cascade for 
apoptosis (Ozben 2007). 
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2.4 BCS1L assembly factor 
BCS1L, a member of the AAA-ATPases superfamily, consists of 419 amino acids. The protein 3D 
structure has not been solved, but sequence analysis shows three major domains: The N-terminal 
domain (first 126aa) containing the signal for the mitochondrial targeting and protein sorting, 
followed by a specific domain for activity and stability (Nouet et al. 2009), and the final C-terminal 
domain (last ~200aa) with two motifs. These two motifs play a role in the substrate binding, 
unfolding, and translocation (Cruciat et al. 1999; Wagener et al. 2011). BCS1L has features of 
AAA-ATPases, which form an oligomeric ring (hexadecamer) structure with a central pore. 
According to studies in yeast, the AAA-domain of the corresponding protein, Bcs1, interacts with 
RISP in the matrix and translocate RISP through its central pore to assemble with pre-CIII2. 
The translocation occurs with ATP hydrolysis (Wagener & Neupert 2012). 
2.4.1 Mutations in BCS1L  
More than twenty recessive disease-causing BCS1L mutations have been reported. They are either 
as compound heterozygous or homozygous resulting in various clinical phenotypes. The most 
severe phenotype is the neonatal GRACILE syndrome in the Finnish population 
(Fellman et al. 1998; Fellman et al. 2008). Patients with GRACILE-like diseases are also found 
with ancestors from Turkey (Serdaroğlu et al. 2016; Kasapkara et al. 2014; Lonlay et al. 2001), 
New Zealand (Lynn et al. 2012), and Spain (Lonlay et al. 2001; Meunier et al. 2013). The majority 
of mutations in the BCS1L cause encephalopathy, hepatic failure, and proximal tubulopathy. Some 
mutations cause muscle weakness and optic atrophy (Meunier et al. 2013) or Björnstad syndrome 
(Table 1). Björnstad syndrome is the least severe phenotype, presenting in newborn infants as 
congenital neurosensory deafness and brittle hair, but compatible with otherwise normal life into 
adulthood (Hinson et al. 2007; Falco et al. 2017). 
2.5 GRACILE syndrome  
A population bottleneck in Finland in the 16th century caused a founder effect in the surviving 
population and resulted in an accumulation of more than 40 recessively inherited mutations,  
so-called Finnish disease heritage (Norio 2003), One of these mutations located in  
BCS1L (c.A232G, Ser78Gly) causes the GRACILE syndrome. The mutated protein has decreased 
capacity to incorporate RISP into CIII2 and thereby leads to CIII dysfunction. The lethal phenotype 
presents typically with severe fetal growth restriction, fulminant lactic acidosis during the first day 
of life, hepatopathy with cholestasis, proximal tubulopathy with typical aminoaciduria, iron 
overload with iron accumulation in liver and spleen (Fellman et al. 1998). Symptomatic treatments 
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including a high amount of bicarbonate had only a short-lasting effect. So far more than 40 severe 
cases with Finnish ancestors have been reported, and the majority of the infants survived less than 
one month (Fellman et al. 1998; Fellman 2002). 




Clinical phenotypes Reference 
Homozygous mutation 
c.148 A>G T50A 
Psychomotor retardation, dysmorphic features, failure to 
thrive, hypotonia, lactic acidosis, mild sensorineural 
hearing loss, and hepatic dysfunction 
(Blázquez et al. 2009) 
c.232A>G  S78G Growth restriction, aminoaciduria, cholestasis, iron overload, lactic acidosis, and early death 
(Fellman 1998, 2002, 
Kotarsky 2010) 
c.296C>T P99L 
Acidosis, hepatic failure, and neurologic symptoms, 
consistent with a Leigh syndrome 
GRACILE- like a disease 
(Kasapkara et al. 2014; 
De Meirleir et al. 2003; 
Serdaroğlu et al. 2016) 
c.385G>A G129R Muscle weakness and optic atrophy. (Tuppen et al. 2010;  Al-Owain et al. 2013) 
c.830G>A S277N Neonatal tubulopathy, hepatic failure, and encephalopathy (de Lonlay et al. 2001) 
c.901T>A Y301N Björnstad syndrome (Siddiqi et al. 2013) 
 





Lactic acidosis, severe failure to thrive, liver 
dysfunction, renal tubulopathy, iron overload in 
aggregated macrophages, neurological symptoms, 
nystagmus, microcephaly, and hypertonia.  
(Visapää et al. 2002; 
Lynn et al. 2012; Ramos-
Arroyo et al. 2009)  
c.399delA 
c.306A > T 
E133DTer25 
G102= 
Encephalopathy, lactic academia, muscular hypotonia, 







Encephalopathy, lactic acidosis, psychomotor delay, 
hypotonia, seizures, failure to thrive, and brittle hair 
Björnstad syndrome 









Encephalopathy, lactic acidosis, psychomotor delay, 





Encephalopathy, lactic acidosis, psychomotor delay, 
hypotonia, seizures, failure to thrive, and brittle hair 
























2.5.1 The mouse model carrying the GRACILE syndrome mutation 
Based on the genotype-phenotype consistency in GRACILE syndrome, Fellman’s group set out to 
develop a mouse model carrying the patient mutation to study disease mechanisms. 
The homozygotes of this knock-in Bcs1lc.A232G mouse model are viable and born healthy, but 
develop growth restriction with hepatopathy and tubulopathy after weaning (Levéen et al. 2011). 
The mutation decreases the amount of BCS1L in liver mitochondria both at pre- and post-weaning 
age, (Levéen et al. 2011). At two weeks of age (P14), the homozygous liver still has a normal RISP 
level in CIII and SC (Davoudi et al. 2014) and a healthy metabolic profile with slightly decreased 
AMP (Kotarsky et al. 2012). After three weeks of age (P21), homozygous mice rapidly developed 
growth failure, lactic acidosis, hepatopathy (with glycogen depletion, steatosis, fibrosis), and 
tubulopathy (Levéen et al. 2011). At the deterioration stage, visceral organs such as liver and 
kidney (Davoudi et al. 2014) had low CIII activity and decreased mitochondrial respiration 
(Levéen et al. 2011). The mice typically survived one month, but about 5% of mice in a mixed 
background to between P70-165 (Levéen et al. 2011). In a congenic background 
(C57BL/6JBomTac) the survival is consistently P35-40 days (Davoudi et al. 2016). 
2.6 Therapeutic strategies for respiratory chain dysfunction 
Therapeutic strategies to improve mitochondrial function include dietary supplementations and 
pharmacological interventions (Nightingale et al. 2016), as well as gene therapy aiming at 
expressing the wild-type protein (Wallace et al. 2010). 
As a symptomatic treatment, supplementation with various pharmacological substances including 
vitamin combinations such as thiamine, riboflavin (Udhayabanu et al. 2017), vitamin C, and 
vitamin E (Parikh et al. 2009; Avula et al. 2014) have been tested with little effect. In some specific 
cases, metabolic modifiers such as coenzyme Q10 (ubiquinone) (Neergheen et al. 2017), 
N-acetylcysteine (Viscomi et al. 2010), L-carnitine (Mermigkis et al. 2013), L-arginine, and 
citrulline (Koga et al. 2005) have been beneficial. L-arginine and citrulline are a suggested 
therapeutic option for mitochondrial encephalopathy with lactic acidosis (MELAS)-related stroke-
like episodes (Koga et al. 2005). Dichloroacetate (DCA) is an option to treat lactic acidosis, which 
is a common problem in mitochondrial disorders. However, DCA can lead to irreversible peripheral 
neuropathy (El-Hattab et al. 2017). Though treatment with these compounds showed some 
beneficial effects, their efficacy is minimal. 
Several studies have tested novel therapeutic strategies in experimental models of various 
mitochondrial diseases. In Drosophila and mouse models, N-acetylcysteine (Wright et al. 2015) and 
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rapamycin (Wang et al. 2016) have been beneficial. Peroxisome proliferator-activated receptor γ 
coactivator 1α (PGC-1α) showed neuroprotective effects by increasing mitochondrial biogenesis 
and function (Dabrowska et al. 2015). Thus, activating PGC-1α is a potential treatment approach 
for mitochondrial dysfunction due to its role in mitochondrial biogenesis. PGC-1α activation 
requires either phosphorylation by AMP-dependent kinase (AMPK) or deacetylation by Sirtuin 1 
(SIRT1) (Puigserver & Spiegelman 2003). Upregulation of AMPK and Sirt1 is possible by AICAR 
and NAD+ precursors (i.e., nicotinamide riboside, NR) respectively. The administration of AICAR, 
NR or PARP inhibitors induced mitochondrial biogenesis in myopathy mouse models 
(Viscomi et al. 2011; Cerutti et al. 2014; Khan et al. 2014). Kennedy et al. reported that ketogenic 
diet (KD) induces the PGC-1α expression via AMP-activated protein kinase (AMPK) signaling 
(Kennedy et al. 2007). KD ameliorated mitochondrial dysfunction and disease progression in 
pyruvate dehydrogenase deficiency, Med30 mutation, and CI deficiency models (Kim & Rho 2008; 
Boison 2017; Clanton et al. 2017).  
Several studies during the past ten years have shown that it is possible to bypass a RC blockage 
using xenogenes such as NADH reductase (Ndi1) or alternative oxidase (AOX). These proteins are 
non-proton-pumping enzymes derived from yeast or lower animals. These enzymes have been 
beneficial in experimental models of RC dysfunction. Ndi1 can bypass a CI defect  
(Perales-Clemente et al. 2008; Sanz et al. 2010), and AOX can bypass CIII and CIV defects  
(Dassa et al. 2009; Fernandez-Ayala et al. 2009). Both proteins can re-establish the electron flow 
and decrease the accumulation of reduced ubiquinone and ROS production. Introduction of adeno-
associated viruses (AAVs) expressing the wild-type form of the mutated gene is theoretically the 
most efficient therapy (Di Meo et al. 2012; Torres-Torronteras et al. 2014) but has technical 
challenges including poor targeting to the affected organ (Mingozzi & High 2011).  
2.7 Alternative oxidases (AOXs) 
Alternative oxidases (AOXs) are membrane-associated proteins (Figure 3a) located on the matrix 
side of IMM. AOX is found in plants (Bahr & Bonner 1973), as well as in some fungi 
(Veiga et al. 2003) and protists (Suzuki et al. 2004; Hellemond et al. 2007). Furthermore, AOX has 
also been discovered in 28 lower animal species representing nine different phyla such as Porifera, 
Placozoa, Cnidaria, Mollusca, Annelida, Nematoda, Echinodermata, Hemichordata and Chordata 
(McDonald & Vanlerberghe 2004 and 2006). However, there is no evidence of AOX in vertebrates 
or arthropods (McDonald et al. 2009). AOX transfers electrons from QH2 to molecular oxygen and 
releases heat, without coupling to proton translocation. Thus, AOX does not contribute to the proton 
gradient and ATP production. 
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AOX functions as a homodimer formed by two monomers bound by an oxidized and covalently 
linked disulfide bond. AOX has a di-iron carboxylate active site formed by four glutamates 
(Glu123, 162, 213, and 266) (Figure 3b) and two histidines (His165, 269). Shiba et al. reported that 
a tyrosine residue (Tyr220) plays a role in the catalytic activity (Shiba et al. 2013). All these 
residues are universally conserved (McDonald & Vanlerberghe 2004). In animal phyla, AOX  
(i.e., Ciona intestinalis AOX) lacks the N-terminal regulatory cysteine (Rhoads et al. 1998; 
McDonald et al. 2009). Generally, AOX remains inactive until the cytochrome-linked RC 
complexes (CIII and CIV) become impaired, resulting in an over-reduced quinone pool 
(accumulation of QH2) (Vanlerberghe 2013). In plants, accumulation of NADH and pyruvate 
activate AOX. Their di-sulphide bond reduction by NADH and stabilization by pyruvate result in an 
active and non-covalently linked AOX homodimer (Vanlerberghe et al. 1995). AOX can maintain 
mitochondrial respiration, decrease ROS by normalizing quinone pool redox status, as well as 




Figure 3. The structure of alternative oxidase (AOX) from Trypanosoma brucei. a) Helix 
bundle of AOX monomer, and b) di-iron carboxylate active site of AOX formed by four glutamate 
residues. The structure was obtained from the protein data bank (PDB.ID:3VV9). 
 
2.7.1 Experimental models with AOX transgene expression 
Ciona intestinalis is an Ascidian (sea squirt) that belongs to the subphylum Urochordata or 
Tunicata. Ciona expresses AOX in several different cell types during all developmental stages 
(McDonald & Vanlerberghe 2004). A CiAOX transgene was first successfully expressed in human 
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cells (HEK293T) in 2006 (Hakkaart et al. 2006). The cells had a normal growth rate, morphology, 
respiration, and RC complex functions. Inhibition of respiration using either antimycin A or cyanide 
showed that AOX rescued respiration and alleviated superoxide overproduction in these cells. This 
study suggested that the redox status of the ETC regulates the activity of CiAOX in the presence of 
pyruvate (Hakkaart et al. 2006). Other studies of CiAOX expression in COX15 or COX10 
(Antonicka et al. 2003a and 2003b; Dassa et al. 2009) deficient human cells, showed partially 
rescued respiration, alleviated glucose and pyruvate dependency, and ameliorated growth defect in 
glucose-restricted condition. Moreover, AOX aided COX15-deficient cells to overcome oxidative-
stress-induced apoptosis caused by antimycin or H2O2 (Dassa et al. 2009).  
Whole-body expression of AOX in Drosophila melanogaster decreased ROS production under 
defective cytochrome c pathway (Sanz et al. 2010; Kemppainen et al. 2014). It also revealed that 
mitochondrial ROS production in flies does not directly regulate lifespan (Sanz et al. 2010). 
Moreover, ubiquitous or nervous system-specific expression of AOX decreased ROS in the dj-1β 
mutant flies, which is a Drosophila model of Parkinson’s disease (Kemppainen et al. 2014). 
Another study showed that AOX prevented the loss of dopaminergic neurons in Drosophila 
(Humphrey et al. 2012).  
A mouse line carrying a single copy of CiAOX in the Rosa26 locus, which expresses AOX in all 
tissues, was recently characterized (Szibor et al. 2016). AOX expression affected neither RC 
complexes nor SC formation. AOX was active only under cytochrome-linked complex inhibition by 
antimycin A or cyanide in these mice. Activated AOX reduced mitochondrial ROS caused by 
succinate oxidation, and restored upstream respiration. The Rosa26AOX mice showed no phenotypic 
changes in extensive phenotyping at the German Mouse Clinic  (Szibor et al. 2016). These studies 
with CiAOX in various systems such as human cells, fly, and mouse suggest that AOX can function 





The overall objective was to examine the disease mechanism in Bcs1l mutant mice and to 
investigate interventions to ameliorate their disease progression.   
 
Specific Aims 
1. To investigate the effect of dietary interventions on disease progression and metabolism in 
Bcs1lp.S78G mice.  
2. To examine the effect of AOX-mediated CIII bypass on disease manifestations in Bcs1lp.S78G 
mice.  




4 Materials and methods 
4.1 Animal strains and husbandry 
For the high-carbohydrate study, we used homozygous Bcs1lc.A232G (Bcs1lp.S78G) mutant mice in the 
C57BL/6JBomTac background (reported as C57BL/6NCrlLtcf in earlier publications) in Lund 
University (I). For the KD and AOX studies, we used the C57BL/6JCrl background in animal 
facilities at the University of Helsinki (II, III) after embryo transfer from Lund. The mice were 
backcrossed for several generations to C57BL/6JCrl before the studies. The mice were housed in 
open cages at Lund facility and in individually ventilated cages at Helsinki facility. The cages were 
maintained on 12 h light/dark cycle at 22-23°C. A standard rodent diet (Teklad Global 18% Rodent 
Diet, Harlan) was used for mice maintenance. Food pellets were provided inside the cage to ensure 
availability of food to the sick mice. 
For the AOX study, we crossed the heterozygous Bcs1lp.S78G mutant mice in the C57BL/6JCrl 
background with AOX transgenic mice in the C57BL/6JOlaHsd background (Szibor et al. 2016) to 
produce Bcs1lp.S78G mice carrying the AOX transgene (double heterozygotes). Crossing the double 
heterozygotes with Bcs1lp.S78G heterozygous mice produced Bcs1lc.A232G homozygotes expressing 
AOX (Bcs1lp.S78G; Rosa26AOX, labeled as GROX). The plain homozygotes (Bcs1lp.S78G) are labeled 
GRAC, the mice carrying the AOX transgene only as AOX, and wild-type mice as WT (III) for this 
study.  
4.2 Genotyping 
DNA isolated either from a piece of tail or an ear punch was used for genotyping Bcs1l  
(Levéen et al. 2011) and AOX transgene (Szibor et al. 2016) as described in articles (I, II,&III). 
4.3 Dietary interventions  
Breeding pairs or litters were randomized to the experimental or control diet. We used a standard 
rodent diet (Teklad Global 18% Rodent Diet, Harlan) as a control diet. As experimental diets, we 
used A 60% dextrose diet (TD05256, Harlan) (I) and a ketogenic diet (TD.96355, Harlan) (II). 
The experimental diets were introduced into the cages before weaning to familiarize the pups to the 
diet (I&II).  
4.4 Monitoring deterioration of the Bcs1lp.S78G mice 
An in-house behavioral scoring method was developed based on common mouse behavioral 
assessment and the characteristic features of Bcs1l mutant mice. It exhibits the sickness of the 
Bcs1lp.S78G mice, which helps to determine the sacrificing point and avoid spontaneous death. 
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Sickness percentage, relative to the littermate controls, was calculated from the behavioral score 
and weight loss. The scoring and calculation methods were described in the article I and used for all 
the studies (I, II, &III) in my thesis. 
4.5 Blood sampling from living mice  
For blood sampling from live mice, the mice were lightly anesthetized with isoflurane (792632 
Sigma-Aldrich), and the tail artery vain was punctured with a needle to obtain a blood drop for 
glucose, lactate and ketone measurements.  
4.6 Plasma and tissue collection 
The mice sacrification was performed either by cervical dislocation or terminal anesthesia with 
pentobarbital. Blood was collected into Li-heparin vials (Vacuette 454089, Greiner Bio-One 
International Gmbh) by cardiac puncture after opening the thoracic cavity. Plasma was isolated and 
stored as described in (I). Organs were snap frozen in liquid nitrogen or fixed in 10% formalin for 
24-72 hours, followed by storage in 70% ethanol for histology studies.  
4.7 Phenotyping at German Mouse Clinic (GMC) 
Mice (n=10 per genotype per sex) were shipped to the GMC at the age of seven weeks and 
maintained under the GMC housing conditions (www.mouseclinic.de) and according to German 
laws until sacrification at week 21. The phenotypic screening was performed between ages  
P56-P112. The experiments conducted at GMC are listed (Table 2), and their protocols are available 
on the GMC website (www.mouseclinic.de). 
4.8 Other experimental methods  
The primary assessments performed in Lund and Helsinki are listed below (Table 3). Their detailed 
protocols are provided in the respective articles. 
4.9 Statistics 
Details on the statistical methods for each study are reported in respective articles (I, II, &III). For 
the unpublished data reported in this thesis, one-way ANOVA followed by Tukey’s test was 
performed for group comparisons. Significant differences between the groups in figures are 
indicated as follows *p<0.05; **p<0.01; ***p<0.001. GraphPad Prism 7 software  
(GraphPad Software Inc, USA) was used to generate the graphs and statistical analysis. Statistical 




4.10 Ethical considerations 
All the experiments were carried out under the guidelines of the Federation of Laboratory Animal 
Science Associations (FELASA) with the approval of respective regional animal research ethics 
committees. The ARRIVE (Animal Research: Reporting of In-Vivo Experiments) recommendations 
and 3Rs (Replacement, Refinement, and Reduction) regulations were followed. The permission for 
HCD study was acquired from the animal research ethics committee of Lund region, Sweden 
(permission M245-11, 19 October 2011), and for KD and AOX gene therapy studies from the 
ethical committee of the State Provincial Office of Southern Finland (permit numbers ESAVI-2010-
07284/Ym-23, and ESAVI/6142/04.10.07/2014). Power and experimental size were calculated 
separately for each study and details are given in respective articles.   
 
Table 2. General methods used at GMC for phenotyping  








     
Behavior  Open Field  59-64 52-56 Dr. Sabine M.Hölter 
Dr. Lillian Garrett 
Dr. Annemarie Zimprich 
Dr. Wolfgang Wurst 
  Acoustic startle and PPI  73-78 66-70 
Neurology  SHIRPA  66-71 59-63 Dr. Lore Becker 
”   Rotarod  66-70 
Metabolism  Calorimetry TSE  80-85 73-77 Dr. Jan Rozman 




  Clinical chemistry   115-120 108-112 
  Blood insulin concentration  115-120  
  Hematology  108-112 
Dysmorphology 
 
 X-Ray  101-106 94-98 Dr. Robert Brommage 
Dr. Helmut Fuchs 
Prof. Dr. Martin Hrabe de 
Angelis 
Nociceptive  Hotplate  101-106 94-98 Dr. Lore Becker 
Eyes  Eye size  108-113 94-98 Dr. Oana Veronica 
Amerie 
Prof. Dr. Jochen Graw 
” 
  Optical coherence tomography  108-113 101-105 
  Scheimpflug analysis  108-113 101-105 
  Virtual drum  108-113 101-105 
SHIRPA: SmithKline Beecham, Harwell, Imperial College, Royal London Hospital, phenotype assessment; TSE-TSE 




Table 3. The list of experiments performed in our studies. 
Experiments HCD KD AOX 
Phenotyping    
     DEXA   III 
     CLAMS   III 
     Echocardiography   III 
     Blood pressure   III 
Clinical chemistry     
     Plasma   III 
     Urine   III 
Histology    
     Immunohistochemistry   III 
     H&E staining I  II III 
     PAS staining I II  
     ORO staining  II III 
     Fibrosis staining    II III 
     Brain immunochemistry   III 
     Lipid peroxidation assay   III 
Protein analyses    
     Western blotting   III 
     Blue native PAGE I  III 
Mitochondrial assessment    
     Electron microscopy  II III 
     CIII activity   III 
     Respirometry I  III 
     Mitochondrial H2O2 emission   III 
Metabolomics    
     Plasma metabolomics I II  
     Tissue metabolomics   III 
Transcriptomics   III 
 
HCD-high carbohydrate diet; KD-ketogenic diet; AOX-alternative oxidase; DEXA- dual-energy x-ray absorptiometry; 
CLAMS- CLAMS Comprehensive Lab Animal Monitoring System; H&E-hematoxylin and eosin;  PAS-periodic acid–





5.1 Plasma metabolome in Bcs1lp.S78G mice with and without dextrose supplementation (I) 
Earlier studies of Bcs1lp.S78G mice have focused on the metabolism and CIII assembly and function 
in liver tissue (Levéen et al. 2011; Kotarsky et al. 2012; Davoudi et al. 2014). In this study, we 
assessed the metabolite changes in plasma, through which the metabolic crosstalk between organs 
occurs. Plasma metabolomics in Bcs1lp.S78G mice revealed increased protein catabolism, defective 
beta-oxidation, and metabolic response to oxidative stress. Our interpretations suggest that the 
glucose-alanine cycle and protein catabolism were high due to the hypoglycemic condition in 
Bcs1lp.S78G mice. Furthermore, we found changes in kidney disease-associated plasma metabolites 
such as phenylalanine, ornithine, and asymmetric-dimethyl arginine. The high-carbohydrate  
(60% dextrose) diet (HCD) on Bcs1lp.S78G mice did not relieve the hypoglycemia, loss of hepatic 
glycogen, micro-vesicular fat accumulation, or decreased mitochondrial respiration. Unexpectedly, 
the HCD slightly decreased survival, despite partially normalizing some plasma metabolites related 
to amino acid metabolism, urea cycle, and neurotransmitter intermediates. 
5.2 Effect of ketogenic diet (KD) in adult Bcs1lp.S78G mice (II and unpublished) 
For the KD feeding study, we used the Bcs1lp.S78G mutants of C57BL/6JCrl background, in which 
the homozygotes survive up to 200 days, probably because they escape the lethal hypoglycemia in 
the juvenile stage. Aiming to bypass glucose metabolism, we fed KD to two mouse groups from 
weaning on. We sacrificed the mice for end-point analyses at P45 (young age) or P95 (adult age) 
and investigated the effect of the diet on hepatopathy (II). The data on adult mice (over P60) are 
summarized as follows. Bcs1lp.S78G mice at P95 had lower blood glucose and increased lactate per 
glucose ratio. The liver enzymes alanine transferase and alkaline phosphatase were high in plasma 
(II, Table 1). Hepatic histology at P95 revealed prominent fibrosis, increased fat, decreased 
glycogen, and increased apoptotic cells (II, Fig 2, Supplementary Fig.2). We found changes in 
plasma metabolites related to protein catabolism, urea cycle, bile acids, and acylcarnitines  
(II, SupFig10B,11B.). Hepatic mitochondria of Bcs1lp.S78G mice were significantly smaller in size 
and had a low number of thickened cristae (II, Fig3). Our findings confirmed the persistence of 
liver dysfunction in adult Bcs1lp.S78G mice. However, the hepatopathy was not severe enough to be 
the cause for the deterioration. 
KD did not affect the growth of Bcs1lp.S78G mice, but robustly induced ketosis. Their liver 
histopathology at P95 showed amelioration of ductular reactions, portal inflammation, fibrosis, and 
apoptosis. It indicated that the effect of KD on hepatopathy was persistent also at adult age  
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(II, Fig1A-D). Moreover, KD rescued mitochondrial morphology (II, Fig3), and partially rescued 
alkaline phosphatase and urea cycle intermediates (arginine, and ornithine) in plasma. Furthermore, 
decreased carnitine and short-chain acylcarnitine levels in plasma of KD-fed Bcs1lp.S78G mice 
indicated altered fatty-acid metabolism (II, SupFig10B,11B.). However, KD-fed Bcs1lp.S78G mice 
deteriorated earlier than the mice on standard/control diet (CD).   
We investigated the KD effect on survival of Bcs1lp.S78G mice using another mouse panel. One 
group of mutant mice (n=4/genotype) were fed on KD until deterioration, and for another group 
(n=3/genotype) we replaced KD at P50 with the CD. On CD, the mutant mice survived to median 
163 days, whereas those on KD started to deteriorate earlier with a median survival of 102 days 
(Figure 4a). The sickness curves, generated based on the combination of sickness score and weight 
loss, suggested intolerance of Bcs1lp.S78G mice to KD over time (Figure 4b). Diet change did not 
affect blood glucose but had a significant impact on blood ketone body and lactate per glucose ratio 
(Figure 4c-e).  
 
Figure 4. Sickness score and survival of Bcs1lp.S78G mice on KD. a) Survival (p=0.0177, Log-
rank, Mantel-Cox Test), b) sickness as determined from behavioral scoring and weight loss, c) 
blood glucose, d) β-hydroxybutyrate, and e) lactate per glucose ratio. KD>CD indicates a shift of 
KD to CD after P50. Bar graphs plotted with mean±SD. One way ANOVA followed by Tukey's 
test for group comparisons. *p<0.05; **p<0.01; ***p<0.001. 
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5.3 Bcs1lp.S78G mice expressing AOX (GROX mice) (III and unpublished)  
5.3.1 AOX extended the survival of Bcs1lp.S78G mice with little effect on growth, whole-body 
metabolism and behavior (III and unpublished) 
To assess the effect of AOX-mediated CIII bypass on disease progression, we bred wild-type and 
Bcs1l mutant mice with and without AOX transgene (labeled in figures, wild-type as WT, AOX+/- as 
AOX, Bcs1lp.S78G as GRAC, and Bcs1lp.S78G; AOX+/- as GROX). We found that AOX expression 
drastically increased the median survival of the Bcs1lp.S78G mice (in GROX mice) from P210 to 
P590 days (III, Fig1B). 
A striking early phenotype of GRACILE syndrome patients and Bcs1lp.S78G mice is their growth 
restriction (Fellman et al. 1998; Visapää et al. 2002; Levéen et al. 2011). GMC performed 
extensive phenotyping of young Bcs1lp.S78G mice (P56-120) and showed decreased body weight, 
lean weight, fat mass, and bone mineral density in the GRAC mice. Interestingly, AOX expression 
did not cause a drastic improvement in body weight (III, Fig1D-G). Behavioral phenotyping 
(between P52-64) showed that the Bcs1lp.S78G mice were less active in the open field test  
(Figure 5a-c). Decreased respiratory exchange rate (in females) and heat production (III, Fig1H, I) 
suggest decreased whole-body energy metabolism. AOX expression in Bcs1lp.S78G mice (GROX) 
had no effect on activity or energy metabolism.  
 
Figure 5. Motor activity in GRAC mice. (a) Total distance traveled by mice in the open field, (b) 
average speed of the mice passing through the center, (c) rearing activity. Bar graphs plotted with 
mean±SD. One-way ANOVA followed by Tukey's test for group comparisons. *p<0.05; **p<0.01; 
***p<0.001.  
 
Hematological analysis of GRAC mice revealed smaller platelet volume and less red blood cell 
distribution width (RDW)(Table 4). Glucose tolerance test showed no change of tolerance (after 30 
or last 90 min of glucose injection), despite low basal glucose level (Table 5 and Table 6). 
Additionally, blood chemistry revealed only marginal alterations in blood electrolytes such as 
calcium, sodium, and slightly increased iron concentration, but significant changes in the liver 
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enzymes such as alkaline phosphatase (ALP), aspartate aminotransferase (ASAT), alanine 
aminotransferase (ALAT), and lactate dehydrogenase (LDH) (Table 5 and Table 6). AOX 
expression (in GROX) did not alter hematology or blood composition. However, it did decrease the 
elevated liver enzymes in females at P108-120.  
 
Table 4. The hematology of male mice (P101 - P121). 
WT AOX GRAC GROX 
Hematocrit  51.9 ± 2.1 51.8 ± 1.7 49.3 ± 2.5 50.5 ± 1.4 
Hemoglobin 16.6 ± 0.6 16.6 ± 0.8 16.0 ± 0.9 16.3 ± 0.6 
MCHCont 15.7 ± 0.5 15.6 ± 0.4 15.7 ± 0.4 16.1 ± 0.4 
MCHC 32.0 ± 1.0 32.1 ± 0.8 32.5 ± 0.8 32.3 ± 0.8 
MCV 49.1 ± 1.5 48.4 ± 1.0 48.3 ± 0.7 50.1 ± 0.7 
Mean platelets volume 6.3 ± 0.1 6.2 ± 0.1 5.9 ± 0.1* 6.1 ± 0.2 
PDW 5.5 ± 0.1 5.4 ± 0.2 5.1 ± 0.1 5.3 ± 0.2 
Platelet large cell ratio 2.7 ± 0.5 2.3 ± 0.6 1.5 ± 0.3 2.0 ± 0.6 
Platelet count  981.6 ± 164.6 1072.7 ± 122.3*** 1049.6 ± 82.1*** 1064.1 ± 70.3 
Red blood cell count 10.6 ± 0.4 10.7 ± 0.3 10.2 ± 0.5 10.1 ± 0.3 
RDW 14.3 ± 0.3 14.2 ± 0.5 12.7 ± 0.4* 12.9 ± 0.3 
White blood cell count  10.0 ± 2.2 10.7 ± 2.6 11.1 ± 1.5 12.1 ± 3.0 
MCHCont: Calculated mean corpuscular hemoglobin content of erythrocytes; MCHC: Calculated mean corpuscular 
hemoglobin concentration of erythrocytes; MCV: Mean corpuscular volume; PDW: Calculated distribution width of 
platelets; RDW: Red cell distribution width (coefficient of variation). Data represented as mean±SD. One-way 

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.2 AOX preserved CIII activity and prevented late-onset cardiomyopathy (III) 
We found that the cause of death of Bcs1lp.S78G mice at P200 was most likely a dilated 
cardiomyopathy. Echocardiography revealed that the cardiac function began to decline after P150 
(III, FigEV1). Histopathology of Bcs1lp.S78G heart at end stage (P200) showed increased fibrosis 
and oxidative stress (4-hydroxynonenal staining) (III, Fig2C-D, and 8E-F). Moreover, heart 
mitochondria were morphologically abnormal, with smaller size and fewer and thicker cristae  
(III, Fig3B-F). 
We sacrificed another mouse group at P150 (at the pre-symptomatic age to cardiomyopathy) to 
analyze the early transcriptional and metabolite alterations, and to assess mitochondrial function 
(III). We found that heart mitochondria in Bcs1lp.S78G mice (GRAC) had significantly lower CIII 
activity (approx. 34% of WT) and respiration (approx. 17% of WT) (III, Fig6). Moreover, 
transcriptomics analysis revealed changes in energy and nitric oxide metabolism (III, Fig5, FigS2, 
and Fig8A). Remarkably, AOX expression in Bcs1lp.S78G mice (GROX) partially rescued cardiac 
mitochondrial CIII activity (approx. to 50% of WT), fully normalized the respiration (100% of 
WT), and, surprisingly, increased the amount of RISP in CIII dimers (III, Fig6). Furthermore, AOX 
expression preserved mitochondrial morphology and tissue histology. We found that AOX 
expression in the Bcs1lp.S78G heart normalized the transcriptional changes related to beta-oxidation, 
amino-acid metabolism, TCA cycle, NO metabolism, and sarcoplasmic-reticulum Ca2+ ion channels 
to WT level. These changes likely contributed to the prevention of lethal cardiomyopathy. 
5.3.3 AOX prevented renal tubular atrophy but not hepatopathy (III) 
Although Bcs1lp.S78G mice (GRAC) survived until P200, their liver fibrosis did not progress to 
cirrhosis. In contrast, the progressive degeneration in proximal tubules of the kidneys resulted in 
severe renal atrophy (III, Fig2A-B) and affected urine filtration parameters (III, FigS1). In both the 
liver and kidney of Bcs1lp.S78G mice, we found a defect in CIII activity and alteration in 
mitochondrial morphology (III). Transcriptomic analysis at post-symptomatic age (P150) showed 
altered cell proliferation, fibrosis, and energy metabolism. Interestingly, we found increased 
glutathione metabolism only in the liver (III, Fig.5). AOX expression did not affect the progressing 
hepatopathy at P200. In contrast, AOX expression rescued kidney mitochondrial morphology; 
decreased proximal tubular cell apoptosis and permanently prevented renal tubular atrophy (III). 
 5.3.4 Effect of AOX on the central and sensory nervous systems (III and unpublished) 
The brain of Bcs1lp.S78G mice (GRAC) showed no signs of severe neurodegeneration but did exhibit 




reported earlier (Tegelberg et al. 2017). AOX expression in Bcs1lp.S78G mice robustly delayed the 
focal astrogliosis (III, Fig3A). 
Detailed phenotyping at GMC revealed that Bcs1lp.S78G mice had no changes in locomotor activity 
or latency on Rotarod drum. These data suggest no defect in neuromuscular function (Figure 6a,b). 
However, decreased prepulse inhibition suggested a defect in acoustic startle reactivity and in 
hearing sensitivity (Figure 6c). Furthermore, the retardation of Bcs1lp.S78G males (GRAC) for second 
heat stimulation in hot plate assay indicated a defect in the neurosensory system (Figure 6d).  
 
Figure 6. Neuronal responses in GRAC and GROX mice. (a) Locomotor activity, (b) latency to 
fall from Rotarod drum, (c) response to prepulse inhibition, and (d) latency to response for second 
heat stimulation on hot plate assay. Bar graphs plotted with mean±SD. One-way ANOVA followed 
by Tukey's test for group comparisons. *p<0.05; **p<0.01; ***p<0.001.  
 
Laser interference biometry on Bcs1lp.S78G mice (GRAC) indicated reduced axial eye lengths 
(distance between cornea and retina) (Figure 7a), reduced lens thickness (Figure 7b) and small 
anterior chamber (Figure 7c) which correlated with small body size. Optical coherence tomography 
(OCT) investigation showed that the posterior part of the eye was healthy with normally developed 
fundus and blood vessels (Figure 7d, e), but a mild change in corneal and retinal thicknesses  
(Figure 7f-i). However, the vision test revealed that Bcs1lp.S78G mice (GRAC) had weaker responses 
than wild-type to the moving stripe pattern of the virtual drum (Figure 7j). AOX expression on 
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Bcs1lp.S78G mice improved the eye-axial length and alleviated the lens thickness abnormality  
(Figure 7a, b). Additionally, AOX expression induced a mild amelioration in vision responses to the 
moving stripe pattern of the virtual drum in males (Figure 7j). 
 
 
Figure 7. Assessment of vision in GRAC and GROX mice. (a-i) Optical coherence tomography 
measurements of (a) axial length, (b) lens thickness, (c) anterior chamber depth, (d) number of 
vessels in fundus, (e) image of posterior part of the eye, thickness of (f) cornea and (g) retina, (h) 
mean density of the left eye’s lens and (i) representative image of lens, and (j) visual response to the 
moving stripe pattern of the virtual drum. Bar graphs plotted with mean±SD. One-way ANOVA 
followed by Tukey's test for group comparisons. *p<0.05; **p<0.01; ***p<0.001 
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5.3.5 Subtle effect of AOX on the cardiac transcriptome in wild-type mice (III and 
unpublished)  
A previous published (Szibor et al. 2016) characterization of the AOX transgenic mice reported no 
overt phenotypic changes. We confirmed that AOX expression in WT mice (pure AOX mice) 
caused no behavioral or whole body metabolic effects. The AOX mice were also histologically 
identical to WT controls. However, we found slight but significant differences (p<0.05, |FC|<1.5) in 
the heart transcriptome of AOX mice with 767 altered genes or transcripts, compared to wild-type 
mice. Most of the genes are annotated (525 genes) and some are uncharacterized genes (242 are 
without name and function). Moreover, the vast majority of these annotated genes had no available 
data on Gene-Ontology enrichment analysis. Interestingly, we found 23 genes associated with 
mitochondrial functions (Figure 8) such as the TCA cycle or respiration, transmembrane 
transportation, DNA repair mechanism, and mitochondrial morphology/migration. 
 
  






6.1 Novel manifestations in Bcs1lp.S78G mice 
During this project, we found in the Bcs1lp.S78G mice (in the C57BL/6JCrl background) several 
novel phenotypes, which have neither been reported in GRACILE patients nor in the earlier mouse 
studies using another genetic background. The GRACILE syndrome patients present with early 
hepatopathy and kidney tubulopathy, but no apparent cardiac abnormality during their short lifespan 
(Fellman et al. 1998; Visapää et al. 2002). Early lethality in infancy likely explains the lack of the 
later-onset phenotypes such as encephalopathy, hearing loss, defective visual senses, and 
cardiomyopathy. However, patients with other BCS1L gene mutations can present with 
encephalopathy (Lonlay et al. 2001; Moran et al. 2010; Fernandez-Vizarra et al. 2007; Tegelberg et 
al. 2017). Björnstad syndrome, also the result of other mutations in BCS1L, manifests with 
sensorineural hearing loss and twisted hair (Hinson et al. 2007; Falco et al. 2017). Also, a patient 
with homozygous BCS1Lp.T70P mutation developed hearing loss (Blázquez et al. 2009). Adult 
patients with the homozygous BCS1Lp.G129R mutation presented with visual problems and bilateral 
optic atrophy (Tuppen et al. 2010). Thus, it seems that Bcs1lp.S78G mice in the C57BL/6JCrl 
background develop most of the phenotypes reported in patients with BCS1L mutations, but also in 
patients with MT-CYB mutations (cardiomyopathy) (Hagen et al. 2013).  
In homozygotes of the C57BL/6JCrl background at P150, we found that CIII activity was less than 
50% of the WT in all affected tissues: heart (34%), kidney (45%), and liver (34%). Moreover, 
Levéen et al. also reported progressive CIII dysfunction in several tissues of Bcs1lp.S78G mice.  
The liver had 50% CIII activity of the WT at disease onset and linear decrease to as low as 20% at 
end-stage disease (P30). At P30, the cardiac CIII activity in Bcs1lp.S78G mice was about 50% of 
normal with no signs of cardiomyopathy, but kidney CIII activity was 40%, and the mice 
manifested tubulopathy (Levéen et al. 2011). Therefore, our findings related to CIII activity are in 
line with the notion that the onset of manifestations requires decreased CIII activity to below 50%.  
6.2 Dietary interventions 
Hypoglycemia is a significant metabolic manifestation of the GRACILE syndrome. Bcs1lp.S78G mice 
in the C57BL/6JBomTac background (I) deteriorate at an early age due to the starvation-like 
conditions and severe hypoglycemia (Levéen et al. 2011). Providing high carbohydrate (60% 
dextrose) diet (HCD) did not improve the glycemic condition. Our results support the conclusion 
from a previous study (Du et al. 2010) that glucose is a metabolically challenging substrate when 
OXPHOS is defective. Increased dietary glucose partially normalized plasma metabolites related to 
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amino acids metabolism and the urea cycle. However, this was insufficient to improve the health of 
the mice. Despite the minor effect of the high-dextrose diet, the plasma metabolomics provided 
novel insight into the metabolic disease of the Bcs1lp.S78G mice. 
Ketogenic diet may stimulate fatty acid oxidation and thereby partially relieve dependence on 
glucose oxidation and PPAR pathway (Kang et al. 2007). Our study (II) showed that KD 
ameliorated hepatopathy and improved mitochondrial structure and function in hepatocytes. 
Other studies have shown the beneficial effects of KD in patients with epilepsy  
(Kang et al. 2007) and mouse models of pyruvate dehydrogenase deficiency (Sofou et al. 2017) 
and mitochondrial myopathy (Ahola-Erkkilä et al. 2010). However, the decreased survival of 
Bcs1lp.S78G mice on KD indicated that the CIII deficiency also caused intolerance to a fat-based 
diet. As we did not assess the effect of KD on other organs, we cannot address the exact cause of 
premature death. The short-term KD feeding (P20 to P50) did not decrease the life-span of 
mutant mice (Figure 4). Increased blood lactate per glucose ratio at adult age and reduced 
survival upon long-term KD feeding indicated adverse effect. Our study suggested that KD may 
have a therapeutic effect on hepatopathy. However, it may cause an adverse effect that prevents 
its use in patients. 
6.3 Transgenic AOX-mediated CIII bypass 
AOX expression dramatically extended the survival of Bcs1lp.S78G mice (GROX) and was beneficial 
mainly for the heart and partially for the kidney. AOX expression rescued mitochondrial structure 
and tissue histology only in heart and kidney tubular cells, suggesting that AOX functioned most 
prominently in high energy-demanding cells. In cardiomyocytes, decreased nitric oxide metabolism 
and improved gene expression of sarcoplasmic reticulum (SR) Ca2+ channels seem to be the 
essential pathways associated with the cardiac functional rescue. In the Bcs1lp.S78G (GRAC) heart, 
transcriptomic alterations in NOS1 and NOS3 suggested the possibility for higher reactive nitrogen 
species (RNS). Other studies have reported the involvement of NOS1 and NOS3 in mitochondrial 
stress in dilated cardiomyopathy (Crespo et al. 2008; Matsa et al. 2013). 
Moreover, acute or long-term regulation of both ROS and RNS play an essential role in controlling 
Ca2+ flux in chronic heart failure (Searles 2002). The cardiac contraction occurs by Ca2+ release and 
uptake in the sarcoplasmic reticulum (SR) through channels such as ryanodine receptor (RyR) 
(Ogawa 1994) and SR Ca2+-ATPase (SERCA/ i.e., ATPA2A)-phospholamban (PLN) complex 
(Frank et al. 2003) respectively. A significant decrease in Ryr2, Atp2a2, and Pln genes in the 
Bcs1lp.S78G (GRAC) heart may have caused a defect in the SR-Ca2+ release and uptake mechanism. 
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Several studies have reported SR Ca2+-ATPase reduction and myocardial Ca2+ handling in dilated 
cardiomyopathy (Gupta et al. 1997; Gregory et al. 2006; Li et al. 2012).  However, it is unclear 
whether increased NOS expression in the Bcs1lp.S78G (GRAC) heart was a cause or an effect in 
relation to the altered SR Ca2+ channels expression. Further examination of NO metabolism and 
signaling in the mutant mice may elucidate this.  
Royo et al. demonstrated in plants that NO and AOX function are linked (Royo et al. 2015). AOX-
mediated respiration in plants (Millar & Day 1996) and in Trypanosoma (Chaudhuri et al. 2006) 
was tolerant to NO stress. Some studies have reported that NO regulates AOX activation, which 
functions as an antioxidant and anti-nitrosative in plants to protect from viral infection  
(Gupta et al. 2012). Thus, the AOX-mediated rescue of NO metabolism in Bcs1lp.S78G heart raises 
the intriguing possibility that an association between AOX and NO exists in these mice as well. 
AOX expression in the Bcs1lp.S78G (GROX) kidney rescued tubular cell mitochondrial morphology 
without normalizing the CI and CII linked respiration in the presence of ADP (state III). Moreover, 
the transcriptomic analysis in the kidney revealed upregulation of cell cycle pathways that indicate 
regeneration or induced cell proliferation. A recent report on the effect of AOX expression on 
muscle-specific COX15 knockout mice also showed that AOX did not normalize mitochondrial 
state III respiration. Instead, AOX had an adverse effect on the myopathy phenotype by reducing 
ROS production and impairing regenerative capacity (Dogan et al. 2018). In contrast, we found that 
AOX expression in the kidney of Bcs1lp.S78G mice (GROX) significantly decreased mitochondrial 
stress (implicated by the rescued mitochondrial structure) and apoptosis but did not affect the 




The studies included in this thesis have further elucidated disease mechanisms and provide novel 
insight into possible treatment strategies for CIII deficiency. Mitochondrial disorders present with 
tissue-specific manifestations, but also with unexpected subtle symptoms. By comparing the 
standardized phenotyping, histological findings, metabolism, transcriptome and mitochondrial 
function in the tissues of Bcs1l mutant mice, we achieved a better understanding of GRACILE 
syndrome pathogenesis. Our main conclusions are: 1) Bcs1lp.S78G mice in C57BL/6JCrl background 
survive to P200 and develop novel late-onset phenotypes including kidney atrophy and dilated 
cardiomyopathy. 2) Dietary interventions have a limited effect on the severe visceral manifestations 
of Bcs1lp.S78G mice. 3) AOX-mediated CIII bypass efficiently prevents or alleviates manifestations 
of CIII deficiency. 4) AOX was mainly beneficial in tissues/cells with high ATP demand, such as 





8 Future prospects 
Recent whole-genome sequencing of the short-lived Bcs1lp.S78G mice, (C57BL/6JBomTac colony), 
revealed a spontaneous variant in mtDNA. The variant emerged more than ten years ago in the in-
house C57BL/6JBomTac colony. We have now verified that the combination of this mtDNA 
variant and the Bcs1lp.S78G mutation resulted in short survival (approx.P35-40)  
(Purhonen et al. under revision). Further characterization regarding the effects of this particular 
mtDNA variant alone and in combination with the Bcs1lp.S78G mutation in the C57BL/6JCrl 
background is ongoing. 
An interesting mechanistic finding from the AOX study was that AOX-mediated respiration might 
be tolerant of nitric oxide (NO) stress. NO is associated with heart failure and neuronal 
degeneration. Further examination of the AOX effect on NO stress might clarify the rescue 
mechanisms and thereby increase knowledge about the possible use of AOX in other mitochondrial 
diseases. However, transgenic AOX expression is not possible in patients nowadays, But further 
studies to develop viral delivery of transgene are ongoing.  
Drosophila is widely used for genetic studies also with mitochondrial disorders  
(Sardiello et al. 2003; Jacobs et al. 2004; Tripoli et al. 2005; Anderson et al. 2008; Angeles et al. 
2014). Drosophila Bcs1l ortholog is 60% identical to human. We have generated a DmBcs1lp.L78X 
mutant fly line using the CRISPR/Cas9 technology. We have also found that a broad Bcs1l knock-
down using RNAi causes pupal lethality and that a homozygous Bcs1lp.L78X mutation causes second-
instar larval lethality (Rajendran et al. unpublished data). These fly strains could be used for cost-
effective pharmacological screening as well as mechanistic studies, the results of which can then be 





GRACILE-oireyhtymä on suomalaiseen tautiperimään kuuluva vaikea vastasyntyneiden 
mitokondriosairaus, jonka aiheuttaa homotsygoottinen pistemutaatio (c.A232G, p.Ser78Gly) 
BCS1L-geenissä. GRACILE-oireyhtymässä mitokondrioiden hengitysketjun  kompleksi III (CIII) 
on viallinen, mikä johtaa vaikeaan aineenvaihdunnan häiriöön, maksa- ja munuaissairauteen ja 
varhaiseen kuolemaan. Sairauden syntymekanismien ja hoitomahdollisuuksien tutkimuksessa on 
osoittautunut erittäin hyödylliseksi hiirimalli, jossa potilaiden pistemutaatio on viety hiiren 
genomiin. Hiirimallissa toistuvat useimmat potilaiden oireet, kuten kasvuhäiriö, alhainen 
verensokeri ja maksa- ja munuaissairaus. Homotsygoottiset hiiret (Bcs1lp.S78G) kuolevat 
C57BL/6JBomTac-kannassa vain 30-40 päivän ikäisinä, todennäköisesti hypoglykemiaan. Sen 
vuoksi tutkimme tässä väitöskirjassa sokeripitoisen ruoan (60 % glukoosia) vaikutusta hiirten 
verensokeriin ja elinikään. Sokerilisä johti kuitenkin jopa hiukan lyhempään elinikään  huolimatta 
siitä, että se näytti korjaavan joidenkin aineenvaiduntatuotteiden pitoisuuksia plasmassa. 
Seuraavissa osatöissä huomasimme, että C57BL/6JCrl-kannassa hiiret elivät viisi kertaa pidempään 
(noin 200 päivää) kuin aikaisemmin Lundin yliopistossa käytetyssä kannassa, ja niille kehittyi uusia 
myöhään alkavia oireita kuten vaikea sydänlihassairaus ja aivomuutoksia. Tässä kannassa tutkimme 
ensin rasvapitoisen (ketogeenisen) ruokavalion vaikutusta maksasairauden etenemiseen. 
Ketogeenisella ruokavaliolla oli selvä myönteinen vaikutus maksasairaukseen ensimmäisten kolmen 
kuukauden aikana, mutta pitkäkestoinen ruokinta aiheutti haittavaikutuksia. Kolmannessa 
osatutkimuksessa risteytimme Bcs1l-mutaatiota kantavia hiiriä vaihtoehtoista oksidaasia (AOX) 
ilmentävän siirtogeenisen hiirilinjan kanssa. AOX voi parantaa hengitysketjun alkuosan toimintaa 
ohjaamalla esimerkiksi CIII:n toimintahäiriön vuoksi pysähtynyttä elektronien kulkua koentsyymi 
Q:lta suoraan hapelle. AOX:n esti kokonaan sydänlihassairauden ja munuaissurkastuman 
kehittymisen Bcs1lp.S78G-hiirille ja hidasti aivomuutosten etenemistä. Sydänsairauden estymisen 
johdosta AOX-siirtogeeniä kantavien mutanttihiirten keskimääräinen elinikä piteni 210 päivästä 
590:een. Väitöskirjatutkimusten tärkeimpiä johtopäätöksiä ovat, että C57BL/6JCrl-kannassa 
Bcs1lp.S78G-hiirillä ilmenee sekä GRACILE-oireyhtymälle tyypillisiä alkuvaiheen oireita, kuten 
kasvuhäiriö ja maksasairaus, että myöhemmin kehittyviä uusia oireita, kuten sydänlihassairaus, joita 
esiintyy muissa CIII-puutossairauksissa. Ruokavaliohoidoilla oli edullista vaikutusta 
maksasairauteen, mutta muutoin vaikutukset olivat vähäisiä tässä vaikean mitokondriosairauden 
mallissa. Sitä vastoin hengitysketjun pysähtyneen elektronivirtauksen palauttaminen AOX-
entsyymin avulla oli ennennäkemättömän tehokas keino hidastaa tai jopa estää pysyvästi vakavia 
oireita, ja vaikutus oli selvin kudoksissa tai soluissa, joilla on suuri energiankulutus, kuten 
sydämessä ja munuaisten tubuluksissa.   
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ஆரா சிய  க  
எ ைடய ஆரா சியான  ரைஸ  எ  ெகா ய மர  ேநாயனா  பாதி க ப ட 
ைம ேடாகா யாவ  ெசய பா ைட ேம ப த ச யான வழி ைறகைள க டறிவேத ஆ .  
ஒ  மரப  பைழ BCS1Lc.A232G, ப ற த ழ ைதகள  ரைஸ  எ  ெகா ய ேநாைய ஏ ப கிற . 
இ த மர  ேநா  ைம ேடாகா யாவ  வாச-ச கிலி ம  III-இ  ேகாளா  ஏ ப வதி  ல  
பல உ கைள ெசயலிழ க ெச  ழ ைதகள  சி  ப வ திேலேய மரண ைத  வைளவ கிற . 
ேநா காண மரப  பைழைடய எலி மாதி கைள பய ப தி இ த ேநாய  வைள கைள 
க டறி ேதா . இ த எலிக  மனதன  காண ப  அேத ேநா  வைள களான வள சி க பா , 
க ர  ைறபா , ம  சி நரக - ழா  ைறபா  ேபா றவ ைற வள ெகா கிறன.  
இ த ேநாயான  மனத களட  வைளவ ப  ேபாலேவ எலிய  வா  நாைள ைற கிற  (35-45 
நா க ). தலி , இ தைகய ஆர பகால மரண தி  க ைமயான இர த  ச கைர  ைறபாேட 
த ைம காரணமாக க டறிய ப டதா , ச கைரய  சமநிைலைய ேம ப வத காக எலிக  
அதிக ச கைர உைடய (ெட ேரா ) உணைவ ஊ டமள  ஆ  ெச ேதா . இ த உண  
இர த தி  சில வள சிைத ெபா கள  மா ற  ஏ ப தியைத தவ ர ஆ ற  வள சிைத மா ற ைத 
ேம ப தவ ைல. இ ேநா காரணயான மரப  பைழைய ம ேறா  மர  ப ல தி  C57BL/6JCrl உ ள 
எலிக  அறி க ப தியேபா , எலிகள  வா நா  தய எலி மாதி ைய கா  ஐ  
மட காக ந த . இ த வா நா  ந  எலிகளைடேய ைள ைறபா  ம  இ தய  
தைசேநா  ேபா ற திய ைறபா கைள ெவள ெகாண த . ேநா  வள சிைய க ப  
ேநா க ட , கீ ேடாெஜ  எ ற அதிக ெகா  ெகா ட உணைவ எலிக  ஊ டமள  ஆ  
ெச ததி , கீ ேடாெஜ  உண  க ர  ைறபா ைட சிறிதள  க ப தியைத  க டறி ேதா . 
ஆனா  ந ட கால கீ ேடாெஜ  ஊ ட  எலிகள  வா  தர ைத  ம  நா கைள  ைற த .  
ம ேறா  ஆ வ , வாச  ச கிலி ெசய பா ைட ேம ப த, மர  பைழ ைடய எலிக  தலாக 
ஒ  மா  ஆ ஸிேட  எ  ப மா ற மரப ைவ அறி க ப திேனா . இத  ரதமான  ம  
III-  ைறபா ைட தவ  எல ரா  ப மா ற ைத ேம ப த ய . இ த மா -ஆ ஸிேட  
ரத  ேநா வா ப ட எலிகள  இ தய தைசேநா  ம  சி நரக - ழா  நலி  ேபா றவ ைற 
றி மாக தவ தேதா , ைளய  சாம ேடாெச ச  படல தி  அ ேராைஸ  அ கள  
வ ைப தாமதி த . ேம , இ த ரத  எலிகள  வா  நாைள சராச யாக 590 நா களாக ந த . 
என  ஆ கள  கிய த மான க  ப  வ வனைவயா . Bcs1lp.S78G மரப  பைழ ஏ ப த ப ட 
எலிக  ம  III ைறபா னா  மனதன  ஏ ப  அைன  வைள கைள  ெகா ள . 
ேம , எலிகள  க ைமயான வள சி க பா  ேம  எ தவைகயான உண  மா ற  ெப தான 
தா க ைத ஏ ப தவ ைல. மா -ஆ ஸிெட  ரதமான  இதய ம  சி நரக ய - ழா  
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